<DOC>
	<DOCNO>NCT01810042</DOCNO>
	<brief_summary>Exudative age-related macular degeneration ( ARMD ) complicate choroidal neovascularization ( CNV ) . Although anti-vascular endothelial growth factor treatment gold standard treatment , recurrence main limitation treatment . The change CNV vascular structure expect provide information regard recurrence . In eye vascular structure clearly see indocyanine green angiography ( ICGA ) , vascular change ranibizumab injection investigate prospectively .</brief_summary>
	<brief_title>Indocyanine Angiographic Changes Choroidal Neovascularization Ranibizumab</brief_title>
	<detailed_description>For patient exudative ARMD CNV , whose vascular structure clearly demonstrate ICGA , ranibizumab inject monthly three time , pro nata 6 month . Vascular structure CNV investigate baseline , 3 6 month use ICGA . Expected number patient 48 eye 4 center , competitively .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1. age &gt; = 50 2 . Visual acuity study eye 20/400 20/40 , eye 20/400 good 3 . Area choroidal new vessel ( CNV ) clearly visible indocyanine green angiography ( ICGA ) 1/2 disc area . 4 . Area CNV clearly visible ICGA half total CNV area . 1 . CNV cause agerelated macular degeneration . ( polypoidal choroidal vascularization , retinal angiomatous proliferation , degenerative myopia etc ) 2 . Blocked fluorescence ICGA half total CNV area . 3 . Disciform scar 4 . Previous antivascular endothelial growth factor ( VEGF ) treatment within 3 month 5 . Previous treatment photodynamic therapy photocoagulation 6 . Previous intraocular periocular injection steroid within 3 month 7 . Previous intraocular surgery except cataract surgery 8 . Vitreoretinal interface disease macula 9 . Presence disease may affect visual acuity ( uveitis , glaucoma , diabetic retinopathy , etc . ) 10 . Uncontrolled periocular intraocular infection 11 . History hypersensitivity ranibizumab treatment 12 . Uncontrolled systemic disease ( hypertension , diabetes mellitus , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>age-related macular degeneration</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>indocyanine angiography</keyword>
</DOC>